Abstract: Plasmid vectors and a process for the preparation thereof are disclosed having the same replication region as pBR322, but which have a substantially higher copy number per cell. The plasmid vectors contain a G.fwdarw.T point mutation at base pair 3074 of the pBR322 sequence which holds back synthesis of the repressor of plasmid replication, and also contain either no tetracycline resistance gene or the tetracycline resistance gene in an inactivated or weakened state.

Abstract: The invention relates to new peptide-aldehydes and a process for the preparation thereof, furthermore to pharmaceutical compositions containing the same.According to a feature of the present invention there are provided new peptide-aldehyde derivatives corresponding to the general formula (I) ##STR1## wherein R.sub.1 represents hydrogen or C.sub.1-6 alkyl group,R.sub.2 stands for C.sub.1-6 alkyl group, furthermore R.sub.1 and R.sub.2 are linked to the amino group of the Xxx alpha-amino acid,Xxx represents a D-phenylalanine residue or a D-alpha-amino acid group having in the side chain a C.sub.1-4 alkyl group,Pro stands for L-proline residue,Yyy stands for L-, D- or DL-arginine residue andA represents an acid residue.The new peptide-aldehyde derivatives of the invention possess valuable anticoagulant activity.

Abstract: The invention relates to a novel process for the preparation of 2-bromo-.alpha.-ergocryptine and its acid addition salt by brominating .alpha.-ergocryptine in such a way that the bromination is carried out at room temperature by using a dimethylsulphoxide-hydrogen bromide mixture containing no more 0.02% of water and, if desired, converting the thus-obtained 2-bromo-.alpha.-ergocryptine to an acid addition salt in a known manner.

Abstract: New intermediate compounds of the formula (I) are disclosed ##STR1## wherein R is hydrogen or C.sub.1 to C.sub.4 alkyl;Z is phenyl optionally substituted by one or more halogen atoms and/or alkyl groups having 1 to 4 carbon atoms; andD is hydroxy, mesyloxy, p-tosyloxy, or halogen; or pharmaceutically acceptable acid addition salt thereof. The compounds of the Formula (I) are intermediates in the preparation of new compounds having anti-ulcer activity.

Abstract: The invention relates to new aqueous pharmaceutical compositions containing as active ingredient a pharmaceutically acceptable complex of a bis-indole compound with a bi- or multivalent metal ion in a therapeutically effective amount. The invention further relates to complexes formed between a bis-indole compound and a bi- or multivalent metal ion.According to another aspect of the invention there is provided a process for the preparation of a pharmaceutically acceptable metal complex of a bis-indole compound and optionally stable aqueous pharmaceutical compositions containing said metal complex, in which a solution of a bis-indole compound or a pharmaceutically acceptable salt thereof in an aqueous medium is reacted with a non-toxic water soluble salt of a bi- or multivalent metal capable of complexation, at a pH of 3.0 to 6.0, optionally in the presence of or followed by the addition of a conventional pharmaceutical carrier and/or further additive, or, if desired, the obtained complex is isolated.

Abstract: The invention relates to pharmaceutical compositions with a neuroleptic action as well as to a process for preparing these compositions.The active ingredients of the compositions of the invention are 2-halo-6-methyl-9-ergolene derivatives of the formula (I), ##STR1## wherein X represents a chlorine, bromine or iodine atom as well as their acid addition salts.The compositions of the invention contain an effective dose of compound of the general formula (I) or an acid addition salt thereof.

Abstract: The invention relates to new apovincaminol derivatives of the formula /I/ ##STR1## wherein R.sub.1 is hydrogen, nitro or halogen,R.sub.2 is a substituted or unsubstituted alkyl or phenyl group,R.sub.3 and R.sub.4 together form a valency bond or each independently represents hydrogen, hydroxyl or an --OR.sub.5 group, in whichR.sub.5 is substituted or unsubstituted alkanoyl or benzoyl group,with the proviso that if R.sub.2 stands for a 3,4,5-trimethoxyphenyl group and R.sub.1 is hydrogen, R.sub.3 and R.sub.4 together do not form a valency bond, or if R.sub.2 is a 3,4,5-trimethoxyphenyl group and R.sub.3 and R.sub.4 both are hydrogen, R.sub.1 is other than hydrogen, nitro or bromine, and acid addition salts thereof.The compounds may be used in the therapy of various skin diseases accompanied by a pathological cell proliferation, preferably psoriasis.

Abstract: The invention relates to new 1-[6-(2'-substituted-5', 6', 7', 8'-tetrahydro-4'-oxo-quinazolino)]-3,4-dihydro-6,7-disubstituted-isoquinol ine derivatives of the formula (I) ##STR1## wherein R.sup.1 and R.sup.2 each independently represents hdyroxyl or alkoxy having from 1 to 6 carbon atoms,R.sup.3 is alky having from 1 to 6 carbon atoms, optionally substituted phenyl, optionally substituted alkylphenyl having from 1 to 4 carbon atoms in the alkyl moiety or an optionally substiutted heterocyclic group,and acid addition and quaternary salts thereof.Compounds of the formula (I) are pharmaceutically active, in particular show spasmolytic, analgesic, antipyretic activity and have a protecting effect in acute alcoholic intoxication.

Abstract: In a method and an apparatus for performing routine analyses such as polarographic or spectrophotometric analysis on a large set of sample solutions filled into separate sample cups being arranged on or shaped in a sample cup holder (101) along a moving path, wherein the samples are in consecutive cycles sucked out of the sample cup (102) by a suction tube (103) and transferred into a common vessel, wherein the analysis will be performed. The vessel (105) has a lower outlet (107) communicating with an analyzer cell (112) or the ambient space over a channel (116) which is only effective if the sample level in the vessel (105) exceeds a certain threshold level, and an aspirating mouth (108) in the upper part of the vessel (105) communicating over a valve (109) with the ambient space. The suction tube (103) has a fixed end coupled to the inlet (106) of the vessel (105) and a free end can be moved into two different working positions.

Abstract: The invention relates to octapeptides of the formulaX-Arg-Val-Tyr-Y-His-Pro-W (I)whereinX is a sarcosyl, lactoyl or hydroxyacetyl radical,Y is cyclopentylglycyl or cyclohexylglycyl, andW is an alanine radical or lactic acid radicalhaving angiotensine-II antagonistic activity.

Abstract: The invention relates to new pregnene derivatives of the general formula (I), ##STR1## wherein R.sup.1 stands for a C.sub.1-4 alkyl group;R.sup.2 stands for a hydrogen atom or a C.sub.2-4 alkanoyl group;R.sup.3 stands for a hydrogen atom, a hydroxyl group or a C.sub.2-4 alkanoyloxy group;A represents a ring of the general formula (1) ##STR2## or a ring of the general formula (2), ##STR3## wherein R.sup.4 means a hydrogen atom or a methyl group;R.sup.5 stands for a hydroxyl group, a C.sub.2-4 alkanoyloxy group or a C.sub.1-3 alkoxy group;R.sup.6 means a hydroxyl group, a C.sub.2-4 alkanoyloxy group, a C.sub.1-3 alkoxy group, an oxo group or a C.sub.2-3 alkylenedithio group;the dotted line optionally represents one or more additional valence bonds, with the proviso that, when the dotted line between C.sub.9 and C.sub.11 represents an additional valence bond, then R.sup.

Abstract: The invention relates to new N-substituted bis(hydroxymethyl)-methyl-isoquinoline derivatives of the formula (I), ##STR1## wherein R.sup.1 and R.sup.2 represent hydroxyl or alkoxy having from 1 to 6 carbon atoms,the dotted line is an optional double bond in the 1,2-position,R.sup.3 is alkyl having from 1 to 6 carbon atoms or aralkyl containing from 1 to 4 carbon atoms in the alkyl moiety, or--if there is a single bond in the 1,2-position--represents a group of the formula ##STR2## in which X is oxygen ifR.sup.4 is alkyl having from 1 to 5 carbon atoms, alkoxy having from 1 to 4 carbon atoms, hydroxyl, phenyl or substituted phenyl; orX is oxygen or sulfur ifR.sup.4 is an --NH.sub.2, --NH--C.sub.1-4 -alkyl, --NH--C.sub.3-6 -cycloalkyl, --NH-phenyl or --NH--C.sub.1-4 -alkyl-phenyl group; andR.sup.5 and R.sup.6 independently stand for hydrogen, alkyl having from 1 to 4 carbon atoms or phenyl, with the proviso that at least one of them is other than phenyl,and salts thereof.

Abstract: The invention relates to fodder additives comprising a compound inducing the microsomal enzyme system of the liver, preferably a compound of the formula (I) ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are identical or different and stand for hydrogen, halogen, trihalomethyl, or alkyl or alkoxy each containing from 1 to 6 carbon atoms;R.sub.4 is phenyl, dialkylaminocarbonyl or alkoxycarbonyl having from 1 to 6 carbon atoms in the alkyl and alkoxy moieties, respectively;R.sub.5 is hydrogen or methyl, or together with R.sub.4 and the adjacent nitrogen atom forms a hetero-ring having up to 8 members;n is 1, 2, 3, 4 or 5;m is 0 or 1;a is 0 or 1,with the proviso that if a=0, R.sub.1 is trihalomethyl and R.sub.2 and R.sub.3 both are hydrogen, preferably in amount of 0.5 to 99% by weight, in an admixture with conventional carriers and/or additives and optionally at least one further active ingredient conventionally used in the animal husbandry.

Abstract: The invention relates to a process for the preparation of a fermentation broth containing coenzyme B.sub.12, with a new, anaerobic, mesophilic, methane-producing mixed micropopulation, under anaerobic, septic conditions, using a new broth containing methanol, precursors and partially known nutrients,In the new process according to the invention the improvement consists in(a) removing 5 to 15 volume percent of the inoculum fermentation broth containing the anaerobic, mesophilic, methan-producing new mixed micropopulation and replacing same with an equal volume of a broth containing cornsteep liquor hydrolysate and/or corn slops of hydrolysate thereof and other known nutrients, the number and concentration of which has been reduced, for 6 to 8 days, and if desired, further manufacturing the fermentation broth removed,(b) after reaching an assimilation velocity of at least 0.15 to 0.2 g methanol/lit.

Abstract: A process is disclosed for the preparation of dimeric alkaloids of formula (II) ##STR1## wherein R stands for methyl or formyl, as well as acid addition salts thereof which comprises oxidizing the vinblastine of formula (III) ##STR2## with chromium (VI) oxide or bichromate or chromic acid alcohol ester in an inert solvent, converting the compound of formula (II), wherein R stands for methyl, so obtained to the acid addition salt and optionally further oxidizing the acid addition salt obtained with an oxidizing agent as defined above and optionally converting the compound of formula (II), wherein R stands for formyl, so obtained to the acid addition salt.

Abstract: The invention relates to new 1-[bis(hydroxymethyl)-methyl]-3,4-dihydro- or -1,2,3,4-tetrahydroisoquinoline derivatives of the formula (I) ##STR1## wherein R.sup.1 and R.sup.2 represent hydroxyl or alkoxy having from 1 to 6 carbon atoms,R.sup.3 is hydrogen or a single electron pair,and the dotted line represents an optional double bond,and salts thereof.The new compounds are useful intermediates in the preparation of other, pharmaceutically active isoquinoline derivatives or are pharmaceutically active themselves.

Abstract: The invention relates to new bis(substituted methyl)-methyl-isoquinoline derivatives of the formula (I) ##STR1## wherein R.sup.1 and R.sup.2 represent hydroxyl or alkoxy having from 1 to 6 carbon atoms,R.sup.3 is hydrogen, aralkyl having from 1 to 4 carbon atoms in the alkyl moiety or a ##STR2## group, in which R.sup.4 is alkyl having from 1 to 5 carbon atoms, phenyl, substituted phenyl or --NH--phenyl,X is oxygen or sulfur,R.sup.7 is hydroxyl, halogen or an ##STR3## group, R.sup.8 is halogen, alkoxy from 1 to 4 carbon atoms or an ##STR4## group, in which X has the same meaning as defined above, andR.sup.9 independently from R.sup.4 may have the same meanings as defined for R.sup.4, or is an --NH(C.sub.1-4 -alkyl) or C.sub.3-6 -cycloalkyl group,and salts thereof. According to another aspect of the invention there are provided processes for the preparation of these compounds and pharmaceutical compositions containing them.

Abstract: The invention relates to new dialkylaminoalkoxybenzylalcohol derivatives of the formula (I) ##STR1## wherein R.sub.1 is hydrogen, halogen, trihalomethyl, alkyl having from one to 4 carbon atoms or alkoxy having from one to 4 carbon atoms;R.sub.2 is halogen, trihalomethyl, alkyl having from one to 4 carbon atoms or alkoxy having from one to 4 carbon atoms;R.sub.3 and R.sub.4 independently stand for an alkyl group having from 3 to 5 carbon atoms; andn is 2, 3, 4 or 5,and acid addition and quanernary ammonium salts thereof.According to another aspect of the invention there are provided processes for the preparation of these compounds.The new compounds provided by the invention are pharmaceutically active, in particular, they are suitable for the treatment of acute ethanolic intoxication. Pharmaceutical compositions containing them as active ingredient are another aspect of the invention.

Abstract: The invention relates to new aminoethoxybenzylalcohol derivatives of the formula (I) ##STR1## wherein R.sub.1 is hydrogen, halogen, trihalomethyl, alkyl having from one to 4 carbon atoms or alkoxy having from one to 4 carbon atoms;R.sub.2 is halogen, trihalomethyl, or alkoxy having from one to 4 carbon atoms;R.sub.3 and R.sub.4 stand for methyl or together with the adjacent nitrogen form an up to 8-membered ring optionally containing oxygen,and acid addition or quaternary ammonium salts thereof.The compounds of formula (I) are pharmacologically active, thus show enzyme-inducing effect. The pharmaceutical compositions containing them as active ingredient are also within the scope of the invention.

Abstract: The invention relates to novel pyrazole derivatives with an ergoline skeleton of the general formula I, ##STR1## wherein x . . . y stands for a ##STR2## R is a hydrogen atom or methyl group, R.sub.1 stands for a hydrogen atom, C.sub.1-4 alkyl, carbethoxy or pyridyl-group,R.sub.2 stands for a hydrogen atom, C.sub.1-4 alkyl, allyl, C.sub.2-4 oxoalkyl-, C.sub.2-4 hydroxyalkyl or C.sub.2-4 hydroxyiminoalkyl group,R.sub.3 stands for a hydrogen atom, C.sub.1-4 alkyl, hydroxy or pyridyl group, furthermoreR.sub.2 and R.sub.3 may stand together for a group of general formula (II), ##STR3## wherein Z stands for a methylene, carbonyl, hydroxymethylene or hydroxyiminomethylene group,R.sub.4 stands for a hydrogen atom or one or two C.sub.1-4 alkyl group(s), andn is 1 or 2,and pharmaceutically acceptable salts thereof.Furthermore the invention relates to a process for the preparation of these compounds.The novel compounds are potent PGF.sub.2.alpha. receptor antagonists.